Total Payments
$130,703
2022 Payments
$1,968
Companies
15
Transactions
138
Medicare Patients
31
Medicare Billing
$8,881
Payment Breakdown by Category
Consulting$70,852 (54.2%)
Other$23,054 (17.6%)
Travel$17,507 (13.4%)
Research$16,846 (12.9%)
Food & Beverage$2,405 (1.8%)
Education$38.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $70,852 | 23 | 54.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,554 | 47 | 15.0% |
| Travel and Lodging | $17,507 | 17 | 13.4% |
| Unspecified | $16,846 | 23 | 12.9% |
| Honoraria | $3,500 | 1 | 2.7% |
| Food and Beverage | $2,405 | 26 | 1.8% |
| Education | $38.00 | 1 | 0.0% |
Payments by Type
General
$113,857
115 transactions
Research
$16,846
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $35,392 | 62 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $31,960 | 17 | $0 (2019) |
| ARIAD Pharmaceuticals, Inc. | $15,095 | 4 | $0 (2017) |
| Genentech USA, Inc. | $10,206 | 8 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $9,588 | 15 | $0 (2020) |
| Millennium Pharmaceuticals, Inc. | $8,400 | 1 | $0 (2017) |
| Spectrum Pharmaceuticals Inc. | $4,611 | 9 | $0 (2017) |
| Foundation Medicine, Inc. | $4,313 | 2 | $0 (2019) |
| Boehringer Ingelheim International GmbH | $4,000 | 11 | $0 (2019) |
| Hoffmann-La Roche Limited | $3,300 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $1,968 | 1 | F. Hoffmann-La Roche AG ($1,968) |
| 2021 | $3,978 | 5 | F. Hoffmann-La Roche AG ($3,978) |
| 2020 | $16,006 | 20 | F. Hoffmann-La Roche AG ($10,901) |
| 2019 | $33,177 | 55 | F. Hoffmann-La Roche AG ($13,903) |
| 2018 | $39,996 | 31 | Takeda Pharmaceuticals U.S.A., Inc. ($27,429) |
| 2017 | $35,579 | 26 | ARIAD Pharmaceuticals, Inc. ($15,095) |
All Payment Transactions
138 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,967.66 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH ADVANCEDMETASTATIC SOLID TUMORS, A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR NTRK1, NTRK2, NT | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,536.87 | Research |
| Study: A PHASE 11B, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB RXDX-101 IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS, WITH OR WITHOUT TRK, ROS1, OR ALK FUSIONS, AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT P | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $749.32 | Research |
| Study: A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $315.89 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH ADVANCEDMETASTATIC SOLID TUMORS, A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR NTRK1, NTRK2, NT | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $276.77 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $99.24 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH ADVANCEDMETASTATIC SOLID TUMORS, A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR NTRK1, NTRK2, NT | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $2,589.00 | Research |
| Study: STARTRK 2 RXDX 101 02 • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $1,631.85 | Research |
| Study: Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children, STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $747.45 | Research |
| Study: STARTRK 2 RXDX 101 02 • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $569.74 | Research |
| Study: LCMC3 • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $99.96 | Research |
| Study: STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $341.49 | Research |
| Study: A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $178.58 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $178.58 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $178.58 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $137.15 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $129.53 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $122.72 | Research |
| Study: A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult • Category: BioOncology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $122.72 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 09/18/2020 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $1,120.00 | General |
| 06/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $548.64 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 06/30/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $448.56 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
| 05/08/2020 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| Category: None | ||||||
| 04/15/2020 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: Oncology | ||||||
| 03/31/2020 | F. Hoffmann-La Roche AG | ROZLYTREK (Biological) | — | In-kind items and services | $2,694.58 | Research |
| Study: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 • Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 | F. Hoffmann-La Roche AG | $4,483 | 8 |
| STARTRK 2 RXDX 101 02 | F. Hoffmann-La Roche AG | $3,336 | 2 |
| A PHASE 11B, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB RXDX-101 IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS, WITH OR WITHOUT TRK, ROS1, OR ALK FUSIONS, AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT P | F. Hoffmann-La Roche AG | $2,537 | 1 |
| AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS, A PHASE I DOSE ESCALATION STUDY OF ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH ADVANCEDMETASTATIC SOLID TUMORS, A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL ENTRECTINIB RXDX-101 IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR NTRK1, NTRK2, NT | F. Hoffmann-La Roche AG | $2,383 | 3 |
| Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children, STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 | F. Hoffmann-La Roche AG | $1,632 | 1 |
| A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC | F. Hoffmann-La Roche AG | $749.32 | 1 |
| LCMC3 | F. Hoffmann-La Roche AG | $569.74 | 1 |
| A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult | F. Hoffmann-La Roche AG | $464.21 | 2 |
| An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements | F. Hoffmann-La Roche AG | $315.73 | 2 |
| AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK123, ROS1, OR ALK GENE REARRANGEMENTS | F. Hoffmann-La Roche AG | $276.77 | 1 |
| STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 | F. Hoffmann-La Roche AG | $99.96 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 1 | 31 | 103 | $45,243 | $8,881 |
Total Patients
31
Total Services
103
Medicare Billing
$8,881
Procedure Codes
1
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 31 | 103 | $45,243 | $8,881 | 19.6% |
About Dr. Robert Doebele, MD
Dr. Robert Doebele, MD is a Medical Oncology healthcare provider based in Aurora, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1952424830.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Doebele, MD has received a total of $130,703 in payments from pharmaceutical and medical device companies, with $1,968 received in 2022. These payments were reported across 138 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($70,852).
As a Medicare-enrolled provider, Doebele has provided services to 31 Medicare beneficiaries, totaling 103 services with total Medicare billing of $8,881. Data is available for 1 year (2020–2020), covering 1 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Aurora, CO
- Active Since 04/07/2007
- Last Updated 11/19/2012
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1952424830
Products in Payments
- ALUNBRIG (Drug) $37,447
- Non-Covered Product (Drug) $16,572
- brigatinib (Drug) $15,095
- Alecensa (Biological) $13,069
- ROZLYTREK (Biological) $10,331
- IMFINZI (Drug) $8,845
- FOUNDATIONACT (Device) $4,313
- GILOTRIF (Drug) $4,000
- TECENTRIQ (Biological) $2,141
- Vitrakvi (Drug) $1,400
- TAGRISSO (Drug) $685.00
- Tecentriq (Biological) $569.74
- ZYKADIA (Drug) $121.44
- Endo GIA (Device) $12.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Aurora
David Camidge, Md, MD
Medical Oncology — Payments: $815,418
Medical Oncology $815,418
Paul Bunn, Md, MD
Medical Oncology — Payments: $568,786
Medical Oncology $568,786
Sami Diab, Md, MD
Medical Oncology — Payments: $263,239
Medical Oncology $263,239
Karl Lewis, Md, MD
Medical Oncology — Payments: $170,530
Medical Oncology $170,530
Dr. Victor Villalobos, M.d., Ph.d, M.D., PH.D
Medical Oncology — Payments: $99,277
Medical Oncology $99,277
Sunnie Kim, M.d, M.D
Medical Oncology — Payments: $72,304
Medical Oncology $72,304